Simponi (golimumab) / Merck (MSD), Tanabe Pharma, J&J - LARVOL DELTA

Real-Life Use of Subcutaneous Biologicals and JAK Inhibitors in IBD Maintenance Therapy: Treatment Continuation, Switching Patterns, and Concomitant Medications. (PubMed, Clin Exp Gastroenterol) - "At 24 months, treatment continuation rates were 51-57% for adalimumab, golimumab, ustekinumab and tofacitinib (in UC); and 71-80% for infliximab, vedolizumab and ustekinumab (in CD). Most switches involved a different mode-of-action. While conventional medications were tapered, IS and 5-ASA may support treatment continuation."

Journal • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis

Combination Therapy in Participants With Active Psoriatic Arthritis Using Subcutaneous Guselkumab and Golimumab: Week 24 Results From the Phase 2a, Multicenter, Randomized, Double-Blind, Proof-of-Concept AFFINITY Study. (PubMed, Arthritis Rheumatol) - "Although the primary endpoint was not achieved, secondary endpoints and exploratory analyses suggest that participants with TNFi-IR PsA, particularly those with elevated CRP, could derive clinically meaningful benefits with guselkumab+golimumab combination therapy, with no new safety concerns, warranting further investigation."

Clinical • Journal • P2a data • Dermatology • Immunology • Infectious Disease • Inflammatory Arthritis • Oncology • Psoriasis • Psoriatic Arthritis • Pulmonary Disease • Respiratory Diseases • Rheumatology • Seronegative Spondyloarthropathies • Tuberculosis

Fighting on all fronts: golimumab to the rescue for steroid-refractory CNS TB–IRIS in an HIV-positive patient facing extreme psychosocial vulnerability (ESCMID Global 2026) - No abstract available

Clinical • Human Immunodeficiency Virus • Infectious Disease

Golimumab, a fully humanized monoclonal TNF-a inhibitor antibody alternative for Hidradenitis Suppurativa (AAD 2026) - "Background: Infliximab (IFX), a chimeric monoclonal antibody targeting tumor necrosis factor (TNF)-α, is a weight-based therapy for hidradenitis suppurativa (HS). Mean cohort age was 35 years; 20 females (74%); racial/ethnic distribution: 12 Black, 3 White, 1 Spanish/Hispanic/Latino, 11 Other. There were significant mean declines at 3-months in HS-PGA (-0.125) and NRS-Pain (-1.76). CRP (13.84), ESR (26.46), and IL-6 (15.13) were significantly decreased at 6 months, as well as 3 months for ESR (6.41) and IL-6 (10.27)."

Dermatology • Hidradenitis Suppurativa • Immunology • CRP • IL6

Clinical Efficacy of Golimumab for Treatment-Refractory Hidradenitis Suppurativa (AAD 2026) - "The cohort included 24 patients with clinical measures documented before and after initiation of golimumab therapy, all of whom had failed adalimumab and 23 of whom had also failed infliximab. Despite being a highly recalcitrant population, 50% of patients achieved IHS4-55 during golimumab therapy, with most responses observed within the first year of treatment. These findings suggest that golimumab may offer benefit for patients with refractory HS who have failed multiple prior biologics."

Clinical • Dermatology • Hidradenitis Suppurativa • Immunology

Effect of Guselkumab and Golimumab Combination Therapy on Magnetic Resonance Imaging-Detected Inflammation and Damage in Phalangeal Joints of the Hands and Feet and Entheses of the Heels Among Participants With Active Psoriatic Arthritis: Findings From the Phase 2a AFFINITY Study (EULAR 2026) - No abstract available

Combination therapy • MRI • P2a data • Immunology • Inflammation • Inflammatory Arthritis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Biomarker-Driven Insights From the Phase 2a AFFINITY Study Evaluating Guselkumab + Golimumab Combination Therapy Versus Guselkumab Monotherapy in Psoriatic Arthritis (EULAR 2026) - No abstract available

Biomarker • Combination therapy • Monotherapy • P2a data • Immunology • Inflammatory Arthritis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Long-term follow-up of patients in the GOLimumab and Methotrexate versus placebo and methotrexate in early, untreated Psoriatic Arthritis (GOLMePsA) trial (EULAR 2026) - No abstract available

Clinical • Immunology • Inflammatory Arthritis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Sequencing Patterns and Efficacy of Biological Therapies and Small Molecules in Patients with Ulcerative Colitis: A Single-Center Retrospective Study (ECCO-IBD 2026) - "Patients underwent 78 courses of advanced therapy (Infliximab 30, Adalimumab 11, Golimumab 8, Vedolizumab 22, Ustekinumab 1, Tofacitinib 2, Filgotinib 2, Ozanimod 2). Conclusion Advanced biologic and small-molecule therapies were effective and generally well-tolerated in patients with refractory UC. Infliximab showed the most durable first-line treatment response, whereas Adalimumab was associated with a shorter treatment duration."

Retrospective data • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

Safety and effectiveness of advanced therapies in patients with Inflammatory Bowel Disease and compensated cirrhosis. Preliminary data from the HEP-IBD study. A study from the young group of GETECCU (ECCO-IBD 2026) - "Consecutive IBD patients with an established diagnosis cirrhosis (Child A or Child B≤8) who received at least induction with infliximab, adalimumab, golimumab, ustekinumab, vedolizumab, tofacitinib, upadacitinib, risankizumab, mirikizumab or filgotinib between January 2000 and September 2024, were eligible. Conclusion This preliminary data indicates that the use of advanced therapies is viable in compensated cirrhosis, with acceptable treatment persistence rates alongside a low risk of hepatic decompensation, particularly for non-anti-TNF therapies. Nonetheless, caution is warranted given the potential risk of adverse events."

Clinical • Metastases • Crohn's disease • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis

Utilising Advanced Therapies in Inflammatory Bowel Disease: Real-World Experience from a UK Centre (ECCO-IBD 2026) - "Biologics and small-molecule medications included anti-TNFα (Adalimumab, Infliximab IV/SC, Golimumab), anti-integrin (Vedolizumab IV/SC), anti-IL12/23 (Ustekinumab), anti-IL23 (Risankizumab), JAK inhibitors (Tofacitinib, Upadacitinib, Filgotinib), and anti-IL23p19 (Mirikizumab)...The observed shift toward subcutaneous Infliximab and Vedolizumab is consistent with global trends that support self-administration and service efficiency...Conclusion Although there is a substantial variability between consultants, the adoption of biologics within this large NHS Trust is consistent with national and international prescribing trends. The results corroborate the need for multidisciplinary assessment and standardization of biologic initiation pathways in order to optimize equality and consistency in advanced IBD treatment."

Clinical • Metastases • Real-world • Real-world evidence • Crohn's disease • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis • IL12A • IL23A

Impact of Corticosteroid Therapy on Long-term Treatment Outcomes in Ulcerative Colitis: A Retrospective Cohort Study (ECCO-IBD 2026) - "Recent availability of carotegrast methyl and oral budesonide has expanded treatment options before AT initiation, necessitating re-evaluation of CS use strategies...AT breakdown: infliximab/adalimumab/golimumab/vedolizumab/ustekinumab/upadacitinib/tofacitinib/filgotinib = 37/20/15/15/7/2/1/1...Cumulative CS dose ≥3,000 mg increases the risk of refractory disease 4.35-fold. These findings suggest that early transition to AT should be considered in elderly-onset patients, and cumulative CS dose of 3,000 mg may serve as a useful threshold for treatment strategy modification, potentially contributing to individualised UC management."

Retrospective data • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

The efficacy of biologics and small molecules in the induction of remission in ulcerative proctitis: an international multicentre study (ECCO-IBD 2026) - "TNFα inhibitors were the most commonly initiated therapies (41.2%; n=47: 38 infliximab, 7 adalimumab, 2 golimumab), followed by JAK inhibitors (21.9%; n=25: 11 filgotinib, 9 upadacitinib, and 5 tofacitinib), ustekinumab (21.1%; n=24), vedolizumab (6.1%; n=7), etrasimod (6.1%; n=7), and mirikizumab (3.5%; n=4). Overall, six treatment discontinuations were recorded (four for lack of efficacy, one for disease progression, one for an allergic reaction), with no additional safety signals observed. Conclusion This multicentre international study demonstrates the effectiveness and safety of advanced therapy in inducing clinical remission in patients with ulcerative proctitis in a real-life setting."

Clinical • Inflammatory Bowel Disease • Ulcerative proctitis • CRP

Case Report of Rapidly Fatal Serratia marcescens Necrotizing Fasciitis (SCCM 2026) - "Serratia marcescens, a gram-negative opportunistic pathogen, is rarely implicated in monomicrobial NSTIs.Description: A 67-year-old woman with rheumatoid arthritis on golimumab, CKD-4, type 2 diabetes, and transfusion-dependent anemia presented with fever, hypotension, and left calf pain...Postoperatively, her multi-organ failure worsened, requiring continuous renal replacement despite broad antimicrobial therapy (meropenem, vancomycin, clindamycin, tobramycin)...Serratia's ability to produce beta-lactamase and cause severe infection highlights the need for rapid surgical intervention and broad antimicrobial coverage. This case underscores the potential for atypical, fulminant infections in TNF-α-inhibited hosts."

Case report • Clinical • Cardiovascular • Chronic Kidney Disease • Diabetes • Hematological Disorders • Hypotension • Immunology • Infectious Disease • Inflammatory Arthritis • Metabolic Disorders • Mood Disorders • Nephrology • Neutropenia • Rheumatoid Arthritis • Type 2 Diabetes Mellitus

Characterization and Optimization of Hidradenitis Suppurativa in an Elderly Cohort (AAD 2026) - "Characterization of 37 elderly HS patients revealed (¯x): age 67.7 years; female:male 1.5:1; 32% self-identified as African American, 22% white, 14% Hispanic/Latino, 5% Asian, 27% other/unknown; BMI: 31.6 kg/m²; age of onset 39.1 years; age at diagnosis 53.6 years(diagnostic delay 14.6 years). At presentation, disease duration was 28.6 years; 35% reported positive family history; HS-Physician Global Assessment(HS-PGA) was 2.9, numerical rating score(NRS)-pain 3.5; erythrocyte sedimentation rate(ESR) 60.6 mm/hr; C-reactive protein(CRP) 5.5 mg/L; interleukin-6(IL-6) 15.9 pg/mL. At enrollment, treatment included antibiotics(topical 100 %, oral 86%, intravenous 22%); anti-androgens 84%; biologics 70% (infliximab 76%; golimumab 12%; fixed-dose 46%)[includes all historical usage]; 84% were HS-PGA≤2."

Clinical • Dermatology • Hidradenitis Suppurativa • Immunology • CRP • IL6

Central Nervous System Demyelination Associated with TNF-Alpha inhibitors: A 20-Year Systematic Review (ACTRIMS Forum 2026) - "Certolizumab showed the earliest onset (mean 8.7 months, SD 13.2), adalimumab (mean 17.7, SD 16.3), etanercept (mean 22.5, SD 34.7), Infliximab (mean 27.7, SD 17.0), & golimumab (mean 32.2, SD 56.0)...For the neurological disorder, only 17.4% of patients required long-term management with disease-modifying therapy, most commonly rituximab (26%), ocrelizumab (15%), and glatiramer with interferon combination (15%)...Following TNF-alpha-inhibitor cessation, 29.03% experienced worsening of their systemic autoimmune condition & 9.6 % required alternative biological therapy, commonly secukinumab, ustekinumab, tocilizumab, or methotrexate... TNF-α inhibitors, though effective for autoimmune diseases, may unpredictably be associated with CNS demyelination. Most often linked with adalimumab, etanercept, and infliximab. While many patients recover after discontinuing steroids, some have persistent deficits, underscoring the need for cautious use and close neurological..."

Review • CNS Disorders • Immunology • Multiple Sclerosis • Ocular Inflammation • Ophthalmology • Optic Neuritis

Demyelination Reported with Biologic Therapies for Rheumatologic and Inflammatory Bowel Diseases: Insights from FAERS (AAN 2026) - "Mechanistic classes included: anti–tumor necrosis factor (TNF)-α agents, anti-integrin antibodies (excluding natalizumab), anti-interleukin agents (including IL-12/23, IL-23, IL-17, IL-6, and IL-1 inhibitors), B-cell targeted therapies (excluding rituximab), and T-cell co-stimulation modulators... Safety signals for demyelination were identified with TNF-α inhibitors (infliximab, adalimumab, certolizumab pegol, golimumab, and etanercept) with a PRR of 7.34 (95% CI: 6.75–7.98), and abatacept, a selective T-cell co-stimulation modulator (PRR: 2.12; 95% CI: 1.41–3.20). No safety signals were observed for IL-12/23 inhibitors (ustekinumab), IL-17 inhibitors (secukinumab, ixekizumab, bimekizumab), IL-23 inhibitors (mirikizumab, guselkumab, tildrakizumab, risankizumab), and anti-α4β7 integrin (vedolizumab). Reporting counts were insufficient for IL-6 inhibitors (tocilizumab and sarilumab), IL-1 inhibitors (anakinra, canakinumab, and rilonacept), and B-lymphocyte stimulator..."

Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Immunology • Inflammation • Inflammatory Bowel Disease • IL12A • IL17A • IL23A

Five-Year Drug Survival and Discontinuation Reasons for Eight Biological Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis: A Retrospective Analysis of 1182 Patients from the Niigata Orthopedic Surgery Rheumatoid Arthritis Database (NOSRAD). (PubMed, J Clin Med) - "Five-year drug survival in the naïve cohort ranged from tocilizumab (50.8%) to golimumab (22.6%); in the switch cohort, from abatacept (42.6%) to infliximab (10.0%). In multivariable Cox analysis of naïve patients, male sex (hazard ratio [HR] = 1.49, 95% confidence interval [CI] = 1.09-2.02), lower baseline 28-joint Disease Activity Score with erythrocyte sedimentation rate (DAS28-ESR) (HR = 0.90, 95% CI = 0.82-0.99), and absence of methotrexate co-therapy (HR = 0.73, 95% CI = 0.55-0.97) predicted discontinuation... Tocilizumab and abatacept demonstrated the highest retention rates in biologic-naïve and switch cohorts, respectively. Early, individualized drug selection and dose optimization are crucial to maximizing long-term bDMARD effectiveness before switching."

Journal • Retrospective data • Immunology • Inflammatory Arthritis • Orthopedics • Rheumatoid Arthritis • Rheumatology

Cost-Utility and Budget Impact Analysis of Tumor Necrosis Factor-Alpha Inhibitors for the Treatment of Refractory Nonsystemic Juvenile Idiopathic Arthritis in Thailand. (PubMed, Value Health Reg Issues) - "Although none of the tumor necrosis factor-alpha inhibitors were cost-effective at the current Thai threshold, adalimumab yielded the most favorable ICER among the evaluated options, whereas infliximab offered a lower budget impact at threshold prices."

HEOR • Journal • Idiopathic Arthritis • Immunology • Oncology • Rheumatology

Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study (clinicaltrials.gov) - P2 | N=8 | Active, not recruiting | Sponsor: University of Washington | Recruiting ➔ Active, not recruiting | N=34 ➔ 8 | Trial completion date: Dec 2027 ➔ Apr 2026 | Trial primary completion date: Mar 2027 ➔ Jul 2025

Enrollment change • Enrollment closed • Trial completion date • Trial primary completion date • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor

Tumor Necrosis Factor-Alpha (TNF-α) Inhibitor Treatment in Hidradenitis Suppurativa: A Population-Based Retrospective Cohort Study of Comorbid Risks. (PubMed, Cureus) - "Using the TriNetX database, 15,416 patients with HS treated with TNF-α inhibitors (infliximab, adalimumab, certolizumab pegol, golimumab) and 201,737 untreated controls were identified. These findings emphasize the need for longitudinal studies examining the biologic safety and development of comorbidities in HS. Awareness of these associations can guide clinical monitoring and patient counseling regarding TNF-α inhibitor therapy."

Journal • Retrospective data • Autoimmune Hepatitis • Dermatology • Gastroenterology • Gastrointestinal Disorder • Hidradenitis Suppurativa • Immunology • Infectious Disease • Inflammatory Bowel Disease • Oncology • Psoriasis • Pulmonary Disease • Respiratory Diseases • Sarcoidosis • Septic Shock • Tuberculosis

PURSUIT 2: A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (clinicaltrials.gov) - P3 | N=84 | Active, not recruiting | Sponsor: Janssen Research & Development, LLC | Trial completion date: Aug 2027 ➔ Feb 2027

Trial completion date • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Pediatrics • Ulcerative Colitis

Biological therapies for inflammatory pouch disorders: insights and outcomes from the RESERVO study of GETECCU. (PubMed, Therap Adv Gastroenterol) - "Overall, 212 lines of treatment were evaluated (95 infliximab, 69 adalimumab, 7 golimumab, 35 vedolizumab and 26 ustekinumab). Biological therapy is a cornerstone in the treatment of pouch disorders, demonstrating consistently high effectiveness. After anti-TNF failure, another mechanism of action should be employed."

Journal • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Oncology • Pain

TREATMENT PERSISTENCE OF FIRST-LINE ADVANCED THERAPIES IN OLDER ADULTS WITH ULCERATIVE COLITIS USING US CLAIMS DATA (ISPOR 2026) - "The most frequently prescribed 1L AT was vedolizumab (n = 445, 48.1%), followed by infliximab (n = 241, 26.0%), adalimumab (n = 111, 12.0%), ustekinumab (n = 105, 11.3%), and tofacitinib (n = 11, 1.2%). Upadacitinib, ozanimod, and golimumab were infrequently prescribed (each n < 10). Real-world treatment persistence of vedolizumab as a 1L AT is longer than or similar to other ATs in older adults with UC."

Clinical • Metastases • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

PURSUIT 2: A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (clinicaltrials.gov) - P3 | N=84 | Active, not recruiting | Sponsor: Janssen Research & Development, LLC | Trial primary completion date: Jun 2024 ➔ Nov 2023

Trial primary completion date • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Pediatrics • Ulcerative Colitis